A turnaround that still needs proving

Healius handed investors two things to chew on with its full-year numbers recently in August 2026: evidence that the Margin repair in its core pathology Business is real, and confirmation it has put its bioanalytical arm, Agilex Biolabs, on the block. Underlying Earnings before interest and tax jumped 76.6 per cent to $30.2 million, and pathology margins widened through the second half. Yet the shares slipped about 3.4 per cent to 43 cents, as a cautious near-term outlook and a large statutory loss reminded the market how much ground the company still has to make up. After selling its Lumus imaging arm, Healius (ASX:HLS) is now essentially a pure-play pathology operator, and the case rests on management’s ability to keep rebuilding wafer-thin margins.

 

What just happened

Reporting for the year to 30 June 2026, Healius lifted underlying Revenue 2.1 per cent to $1,373.2 million and underlying EBITDA 8.1 per cent to $258.6 million. The standout was the pace of margin recovery: pathology EBITDA margin rose 80 basis points to 18.6 per cent, and the second-half EBITDA margin reached 19.7 per cent, up 210 basis points on the first half’s 17.6 per cent.

Alongside the result, the company said it had appointed UBS to explore a sale of Agilex Biolabs after what it described as strong, unsolicited interest from potential buyers. Agilex sits as a standalone unit, so a divestment would not touch the pathology network. An update is promised before the annual general meeting.

 

Why it matters

For a business that spent recent years bleeding margin, direction of travel counts. Chief executive Paul Anderson framed the year around “margin recovery through improved revenue quality and strict cost discipline,” and the second-half figures suggest the discipline is landing. An Agilex sale would sharpen that focus further, turning Healius into a single-segment pathology company with a cleaner Balance Sheet and, potentially, cash to return.

 

The numbers that matter

Pathology, now the engine room, generated $1,329.6 million of revenue, up 1.8 per cent, with EBITDA of $247.9 million, roughly $15 million higher than a year earlier. Pathology EBIT rose 65.3 per cent to $23.8 million, though the segment’s EBIT margin remains slender at 1.8 per cent, up 70 basis points. Agilex, the asset now for sale, punched above its weight: revenue of $43.6 million (up 14.1 per cent), EBITDA of $10.7 million and EBIT of $6.4 million, more than double the prior year, on a 14.7 per cent margin.

Below the underlying line, the statutory picture was ugly. Healius booked a net loss of $415.6 million after discontinued operations, and a reported EBIT loss of $328.9 million, weighed down by the accounting on the Lumus disposal and restructuring. On cost-out, management delivered $24.4 million of annualised corporate savings against an original $15–20 million target.

The balance sheet moved the wrong way but for understandable reasons. Healius swung from net cash of $57.2 million a year ago to net Debt of $32.8 million, after one-off outflows including an ATO settlement and about $22 million of Lumus completion adjustments. Leverage sits at 1.2 times, comfortably inside banking covenants. That position followed the roughly $965 million sale of Lumus Imaging to Affinity Equity Partners on about 17 times FY24 EBITDA, which completed in 2025 and delivered close to $800 million of net proceeds used to cut debt.

 

The bigger industry picture

Australian pathology is a high-volume, low-margin trade squeezed between rising wages and a fee schedule that barely moves. Most tests are bulk-billed against Medicare rebates that have been frozen or lightly indexed for years, so operators cannot readily pass through cost increases. Healius flagged that the federal budget delivered no new pathology funding, and that a Fair Work Commission decision on gender-based undervaluation is pushing wages higher, with a roughly $15 million cost impact baked into the coming year. Labour ran at 49.7 per cent of revenue.

The sector is effectively a three-horse race. Market Leader Sonic Healthcare, with its diversified global footprint, and Australian Clinical Labs both compete hard for GP referrals and collection-centre footprint. Scale, network efficiency and digital throughput are the levers, and Healius is the smaller domestic player trying to close a margin gap on more efficient rivals.

 

The bull case

The optimistic reading is straightforward: Healius is early in a self-help story with real operating leverage. The second-half margin step-up shows cost discipline flowing through, and management has completed the major phase of a digital program, with more than 80 per cent of episodes now running through its Medway platform, a plank for further automation and AI-driven efficiency. Anderson has signalled an ambition to reach mid-to-high single-digit EBIT margins by around December 2028; on pathology revenue of $1.3 billion-plus, each point of margin is worth over $13 million. A clean Agilex sale would add cash and simplify the equity story.

 

The risks

The margins that are recovering are still thin enough that a single adverse input can erase the gains. Wage inflation, crystallised by the Fair Work decision, is the clearest threat, and there is no funding relief in sight from Canberra. Volumes were soft, and revenue growth is leaning on price and mix rather than throughput. The statutory loss and the move into net debt leave little balance-sheet slack, and an Agilex sale is not guaranteed to complete on attractive terms. Reaching the 2028 margin target assumes years of uninterrupted execution against structural sector headwinds.

 

What happens next

Watch for, in rough order: an update on the Agilex sale process before the AGM; formal FY27 guidance, with management pointing to a consensus EBIT figure of about $39.7 million that already absorbs the Fair Work cost; the AGM itself and any capital-management signal; further evidence that the second-half margin run-rate holds into the first half of FY27; and progress on digital and automation benefits from the Medway rollout.

 

Conclusion

Healius enters FY27 as a leaner, more focused company than it was two years ago, with the imaging sale behind it and pathology firmly at the centre. The full-year result offered genuine signs that margin repair is under way, particularly the second-half improvement, and the potential Agilex divestment could tidy the story further. But the market’s muted response captures the balance of evidence: an operator still generating razor-thin pathology margins, carrying a heavy statutory loss, and facing wage pressure with no funding relief. The turnaround is credible but unfinished, and the next two reporting periods, together with the Agilex outcome, will show whether management can convert a promising half into a durable trend.